Zilast 100 Tablet contains Cilostazol 100 mg, a phosphodiesterase III inhibitor indicated primarily for the treatment of intermittent claudication due to peripheral arterial disease. Cilostazol exerts its therapeutic effect by inhibiting platelet aggregation and inducing vasodilation, thereby improving blood flow to the affected limbs and reducing symptoms such as pain and cramping during walking. The drug acts by increasing cyclic adenosine monophosphate (cAMP) levels in platelets and vascular smooth muscle cells, leading to inhibition of platelet activation and relaxation of vascular smooth muscle. Zilast 100 is typically administered orally, with the recommended dose being 100 mg twice daily, taken at least 30 minutes before or two hours after meals to enhance absorption. It is contraindicated in patients with heart failure due to the risk of increased mortality in this population. Common adverse effects include headache, diarrhea, palpitations, and dizziness. Caution is advised in patients with bleeding disorders or those on concurrent anticoagulant therapy. Regular monitoring and clinical assessment are recommended to evaluate therapeutic response and detect any potential adverse reactions. Zilast 100 should be used under medical supervision, ensuring appropriate patient selection and adherence to prescribed dosing regimens.